Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01112293 · ClinicalTrials.gov registry record · Phase 2
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
A Phase 2 study of Pleural Malignant Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01112293: Completed Phase 2 study of Pleural Malignant Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01112293 is a Phase 2 study of Pleural Malignant Mesothelioma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 14 participants, below the 64-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01112293, a Phase 2 study of Pleural Malignant Mesothelioma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA. Approximately 40 people will be enrolled on this study at the University of Pennsylvania (Main Institution/Coordinating Site) and the University of Chicago (Participating Institution). We expect about 20 subjects to be enrolled at each institution.
Primary Outcome
The fraction of subjects surviving 3 months without disease progression.
Conditions Studied
Interventions
- DRUG GC1008
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
What the finished NCT01112293 record still lists
NCT01112293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 64-participant average among 4 other Pleural Malignant Mesothelioma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Pleural Malignant Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which GC1008 is the first listed.
NCT01112293 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01112293 about?
NCT01112293 is a clinical study titled "Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma". This study is being conducted to evaluate the overall safety and effectiveness of an investigational drug, GC1008, in patients with mesothelioma. An investigational drug is one that has not been approved by the FDA. Approximately 40 people will be enrolled on this study at the University of Pennsylv...
What is the current status of trial NCT01112293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2010-04. Estimated completion is 2014-12.
What conditions does trial NCT01112293 study?
This clinical trial studies the following conditions: Pleural Malignant Mesothelioma.
What interventions are being tested in trial NCT01112293?
The interventions under investigation include: GC1008 (DRUG).
Who is sponsoring clinical trial NCT01112293?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01112293 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleural Malignant Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Patients With Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
-
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
-
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia